GALS identifies the most innovative, driven, and exciting companies to participate in the GALS program. Based on each company’s goals and needs, we offer individualized support in various areas, including strategic guidance, operational support, and access to our global network of experts and resources, to integrate companies into the U.S. life science ecosystem.

GALS Companies

GALS Alumni

COMPANY NEWS

Artikel: “Wir entziehen dem Tumor die Tarnung”

Neues Verfahren von Rigontec in der Immunoonkologie


Read more

Adhesys Medical acquired by Grünenthal Group
April 7, 2017

The Grünenthal Group today announced the acquisition of the company Adhesys Medical to expand its pipeline of medical devices for its business with surgeons The acquisition of Adhesys Medical and its highly innovative pipeline of surgical sealants, together with the underlying technology platform, allows Grünenthal to tap into the global $1 billion surgical sealants market


Read more

The Berlin Institute of Health adopts labfolder’s digital lab data management platform
April 6, 2017

The Berlin Institute of Health (BIH) adopts the digital laboratory data management platform from the Berlin-based start-up labfolder


Read more

Press Release: Adhesys Medical Announces Collaboration with GALS
March 14, 2017

Adhesys Medical, a medical device company developing the next generation of surgical adhesives, announced today its acceptance into the German Accelerator Life Sciences (GALS) program.


Read more

InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies
March 6, 2017

InGeneron Inc. announced that Sanford Health, one of the largest integrated healthcare providers in the U.S., has invested $20 million in the company in the form of a Series D financing.


Read more

Scopis Receives FDA 510(K) and Health Canada MDL Clearance
February 28, 2017

Scopis announced that it has received 510(K) clearance from the U.S. Food and Drug Administration and Health Canada Medical Device License for its breakthrough next-generation surgical navigation products for ENT surgery.


Read more

Scopis Initiates Collaboration with the German Accelerator Life Sciences
January 23, 2017

Scopis, a tech company specializing in surgical navigation and medical augmented reality, announced today its collaboration with the German Accelerator Life Sciences (GALS) program.


Read more

Personal MedSystems GmbH gains international consortium and closes series B financing.
January 17, 2017

Personal MedSystems GmbH has closed their Series B financing with a volume of 5 million EUR. A further 0.7 million EUR from existing investors is expected. The capital will be used for sales growth and continued innovation on its technology and data platform.


Read more

InGeneron Initiates Collaboration with German Accelerator Life Sciences
December 5, 2016

InGeneron, a regenerative medicine and biotechnology company, today announced its acceptance to the German Accelerator Life Sciences (GALS) program. InGeneron will be establishing an additional U.S. presence in Cambridge, MA.


Read more

InGeneron Presents Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS
November 21, 2016

InGeneron, Inc. announced today the presentation of initial data from an investigator initiated case series using its proprietary adipose-derived regenerative cell (ADRC) technology for the treatment of facet joint syndrome, one of the major causes of chronic back pain.


Read more

PEPperPRINT: Hit Validation and Affinity Determination Service
November 17, 2016

PEPperPRINT offers the confirmation and affinity determination of primary hit peptides to a target protein or antibody in a soluble, homogenous format using fluorescence polarization as quantitative measure for protein-peptide binding.


Read more

Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer
November 15, 2016

Rigontec announced today that Dr. Jörg Vollmer has joined the Company as Chief Scientific Officer. Dr. Vollmer brings to Rigontec more than 17 years of drug discovery and development experience


Read more

Scopis introduces TGS®-Target Guided Surgery ENT Navigation to the US market
November 2, 2016

Scopis introduced their TGS® - Target Guided Surgery navigation system to the large number of delegates in attendance at the 120th AAO-HSNF Annual Meeting. Delegates had the opportunity to use Scopis Building Blocks® planning software that incorporated the new International Frontal Sinus Anatomy Classification (IFAC).


Read more

Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics
September 6, 2016

Rigontec announced that it secured EUR 15 million in a third and final closing of its Series A round. The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic.


Read more

Scopis is a Finalist at the German Founders’ Award 2016
May 23, 2016

Scopis is one of the last three competitors for the German Founders’ Award 2016 in the Climber category.


Read more

PEPperPRINT Product Update: PEPperCHIP® Autoimmune Epitope Microarray 3.0 released
May 18, 2016

The new PEPperCHIP® Autoimmune Epitope Microarray 3.0 covers 4,287 linear autoimmune epitopes including 286 citrullinated peptides as well as the corresponding arginine variants.


Read more

Scopis GmbH awarded the Fraunhofer Start-up Prize
February 23, 2016

The Fraunhofer Start-up Prize recognizes the current success and phenomenal development of the Fraunhofer spin-off on the international market for medical technology.


Read more

Biotech Showcase™ 2016: Interview: Rigontec details immuno-oncology strategy
February 3, 2016

Rigontec GmbH CEO Dr. Christian Schetter explains to Mike Ward, Informa Pharma Insights global director of content, how his company is developing a new class of RNA-based immunotherapeutics to treat cancers and viral diseases by targeting RIG-I.


Read more

First Four Companies Selected to Participate in the German Accelerator Life Sciences Program in Cambridge
January 13, 2016

During the 34th JP Morgan Healthcare Conference, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. AYOXXA Biosystems, PEPperPRINT, Personal MedSystems, and Sonormed will receive support tailored towards the specific needs of each company.


Read more

Sonormed’s innovative Tinnitus-treating app wins award at SXSW
March 19, 2015

A soon-to-be-released app for treating tinnitus turned heads at the South-by-Southwest Music, Film and Interactive Festival (SXSW) in Austin, Texas for its innovative approach to treatment. With Tinnitracks, treating tinnitus is as simple as listening to your favorite music for at least one hour per day for six months in a quiet surrounding.


Read more